LONDON, Sept. 16, 2020 /PRNewswire/ -- Smith+Nephew
(LSE:SN, NYSE:SNN), the global medical technology business, today
welcomes the announcement that its campaign to develop and promote
the T.I.M.E. clinical decision support tool (CDST)1 was
awarded Most Innovative in the category Excellence in Reputation
& Thought Leadership at the 2020 Gartner Communications Award
Ceremony. The campaign was chosen among 200 entries from
organisations across 30 countries.
Smith+Nephew's campaign addressed the finding that 40% of wound
care specialists did not routinely use wound assessment tools
leading to considerable variability in clinical
practice.2
"To help improve consistency in front line wound care, we
developed the T.I.M.E. CDST, a simple 5-step framework that applies
the principles of wound bed preparation as part of holistic patient
care. We ensured clinical relevance by involving international
clinical expert practitioners throughout the 3-step development
process of 1) identifying the issue of variation in practice
2) developing, validating and launching the tool and 3) providing
proof of concept by implementation in daily practice." said the
programme leader, Claudia Matei,
Global Marketing Director, Smith+Nephew.
The KOL-endorsed two-year programme has produced outstanding
customer engagement. The clinical experts delivered eight
publications, and the learnings and recommendations have been
written up in a global consensus document and published by the
World Union of Wound Healing Societies (WUWHS).1-8 The
communication strategy delivered a measurable shift in awareness of
the new Smith+Nephew direction internally and externally.
"The evidence pertaining to the impact of the T.I.M.E. CDST is
growing and outcomes achieved show that it increases practitioner
confidence and promotes evidence-based decision-making, all which
have resulted in greater consistency of care delivery and enhanced
clinical outcomes.8" said Prof. Zena Moore Professor,
Head of the School of Nursing and Midwifery, and Directors of the
Skin Wounds and Trauma (SWaT) Research Centre, Royal College of Surgeons in Ireland (RCSI)
University of Medicine and Health Sciences.
"The Smith+Nephew team is very excited to be judged Most
Innovative." said Kirsti Harefallet, Global Director Marketing
Communications, Smith+Nephew. "The award recognises the importance
of identifying key drivers for Smith+Nephew's most important
audience segments, exploring new and creative uses of PR and social
media, leveraging internal and external partnerships to build
stakeholder engagement, and demonstrating the value of reputation
to business outcomes. We appreciate this recognition of our
effective planning and implementation of this programme to deliver
on Smith+Nephew's mission of a Life Unlimited."
To learn more about T.I.M.E. CDST please visit
https://www.smith-nephew.com/key-products/advanced-wound-management/time/
References
- Moore Z, Dowsett C, Smith G, et al. TIME CDST: an updated tool
to address the current challenges in wound care. J Wound Care 2019;
28(3):154-161.
- Ousey K, Gilchrist B, Jaimes H. Understanding clinical practice
challenges: a survey performed with wound care clinicians to
explore wound assessment frameworks. Wounds International.
2018;9(4):58-62.
- Swanson T, Duynhoven K, Johnstone D. Using the new T.I.M.E.
Clinical Decision Support Tool to promote consistent holistic wound
management and to eliminate variation in practice in Victoria, Australia: Part 1. Wounds
International. 2019;10(2):38–47.
- Woo K. Using the new T.I.M.E. Clinical Decision Support Tool to
promote consistent holistic wound management and eliminate
variation in practice: Part 3 at the West Park Healthcare Centre,
Chronic Care and Rehabilitation Hospital, Canada. Wounds International.
2019;10(3):48-55.
- Jelnes R, Halim AA, Mujakovic A, et al. Using the new T.I.M.E.
Clinical Decision Support Tool to promote consistent holistic wound
management and eliminate variation in practice: Part 2 at the
Sygehus Sønderjylland Hospital, Sønderborg, Denmark. Wounds International.
2019;10(3):40–44.
- Blackburn J, Ousey K, Stephenson J. Using the new T.I.M.E.
Clinical Decision Support Tool to promote consistent holistic wound
management and eliminate variation in practice: Part 5, survey
feedback from non-specialists. Wounds International.
2019;10(4):40–49.
- Walters S, Snowball G, Westmorland L, Spanjers J, Rozells A,
Carville K. Using the new T.I.M.E. Clinical Decision Support Tool
to promote consistent holistic wound management and eliminate
variation in practice: Part 4 at Silver Chain Group, Perth, Australia. Wounds International.
2019;10(4):32-39.
- World Union of Wound Healing Societies (2020) Strategies to
reduce practice variation in wound assessment and management: The
T.I.M.E. Clinical Decision Support Tool. London: Wounds International. Available at:
www.woundsinternational.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that
exists to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 17,500+ employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Advanced Wound Management and Sports
Medicine & ENT.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.1 billion in 2019.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us
on Twitter, LinkedIn,
Instagram or Facebook.
To learn more about how we can help you get CLOSER TO
ZERO◊ delay in wound healing, please visit
www.closertozero.com
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
27284 September 2020
View original content to download
multimedia:http://www.prnewswire.com/news-releases/smithnephews-time-cdst-launch-judged-most-innovative-at-the-2020-gartner-communications-awards-301131789.html
SOURCE Smith & Nephew plc